MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27451
Abstract: Unraveling molecular mechanisms that regulate tumor development and proliferation is of the utmost importance in the quest to decrease the high mortality rate of adrenocortical carcinomas (ACC). Our aim was to evaluate the role of… read more here.
Keywords: pathway inhibition; treatment; mapk; erk pathway ... See more keywords
Probing the multimodal fungiform papilla: complex peripheral nerve endings of chorda tympani taste and mechanosensitive fibers before and after Hedgehog pathway inhibition
Sign Up to like & getrecommendations! Published in 2021 at "Cell and Tissue Research"
DOI: 10.1007/s00441-021-03561-1
Abstract: The fungiform papilla (FP) is a gustatory and somatosensory structure incorporating chorda tympani (CT) nerve fibers that innervate taste buds (TB) and also contain somatosensory endings for touch and temperature. Hedgehog (HH) pathway inhibition eliminates… read more here.
Keywords: pathway inhibition; fungiform papilla; inhibition; chorda tympani ... See more keywords
Anti-inflammatory effects of an optimized PPAR-γ agonist via NF-κB pathway inhibition.
Sign Up to like & getrecommendations! Published in 2020 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2020.103611
Abstract: In our previous study, a PPAR-γ agonist (+)-(R,E)-6a1 was elaborated as an anti-inflammatory lead. However, in silico analysis showed that (+)-(R,E)-6a1 lacks key hydrogen bonding with Tyr473 of PPAR-γ LBD (ligand binding domain). To facilitate… read more here.
Keywords: anti inflammatory; pathway inhibition; inhibition; via pathway ... See more keywords
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.
Sign Up to like & getrecommendations! Published in 2019 at "Thrombosis research"
DOI: 10.1016/j.thromres.2019.09.033
Abstract: This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been… read more here.
Keywords: rivaroxaban plus; pathway inhibition; dual pathway;
State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism.
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and haemostasis"
DOI: 10.1055/a-1778-1083
Abstract: Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived… read more here.
Keywords: pathway inhibition; dual pathway; thromboembolism; venous thromboembolism ... See more keywords
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0040-1713376
Abstract: Despite advances in secondary prevention strategies in patients with cardiovascular disease, the residual risk of recurrent atherothrombotic events remains high. Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary… read more here.
Keywords: pathway inhibition; patients atherosclerotic; atherosclerotic disease; vascular protection ... See more keywords
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.1048
Abstract: Patients with atherosclerotic cardiovascular disease (ASCVD) are at a high-risk of experiencing a major adverse cardiovascular event, with 1 in 10 individuals experiencing an event within four years (1). To address this risk of secondary… read more here.
Keywords: pathway inhibition; registry; heart; dual pathway ... See more keywords
Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001382
Abstract: Abstract: Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these… read more here.
Keywords: pathway inhibition; pathway; dual pathway; rivaroxaban aspirin ... See more keywords
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Haematology"
DOI: 10.1111/bjh.19380
Abstract: Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients with refractory systemic disease and/or LCH‐associated neurodegeneration.… read more here.
Keywords: pathway inhibition; mapk pathway; cell histiocytosis; langerhans cell ... See more keywords
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-006555
Abstract: With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment settings is… read more here.
Keywords: addressing resistance; inhibition considerations; trial; resistance ... See more keywords
Abstract 81: High-resolution monitoring of B cell isotype switching for biomarker analysis of adenosine pathway inhibition immunotherapy
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-81
Abstract: Background B cell isotype switching gives rise to IgG-, IgA-, and IgE-expressing B cells and is an essential step in generating effective humoral responses to antigen challenge. Within the tumor microenvironment, extracellular adenosine may contribute… read more here.
Keywords: pathway inhibition; adenosine; cell; isotype switching ... See more keywords